{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:21:25Z","timestamp":1794014485816,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody\u2013drug conjugates (ADCs) represent a rapidly evolving therapeutic modality, combining the selective targeting of monoclonal antibodies with highly potent small molecule payloads. Their inherent structural complexity demands a sophisticated and multi-faceted bioanalytical approach spanning preclinical discovery through late-stage clinical development. This white paper, developed by the ADC Working Group of the AAPS bioanalytical community, comprising over 100 members from industry, contract research organizations (CROs), and regulatory agencies, provides updated recommendations for ADC bioanalysis. Building upon the foundational 2013 AAPS position paper and recent publications governing regulatory frameworks on PK considerations, this work addresses advances in bioanalytical quantitation strategies for total antibody (tAb), conjugated ADC, free (unconjugated) payload, and drug-to antibody ratio (DAR); novel immunogenicity assessment considerations; soluble target interference; critical reagent lifecycle management; payload-specific stability requirements; cross-validation strategies; and regulatory considerations. The recommendations presented herein reflect over a decade of scientific progress and are designed to serve as a comprehensive, empirically validated, and industry aligned bioanalytical framework for contemporary ADC drug development.<\/jats:p>","DOI":"10.1208\/s12248-026-01268-1","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:55:23Z","timestamp":1782921323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Updated Recommendations for the Bioanalysis of Antibody\u2013Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-598X","authenticated-orcid":false,"given":"Jim X.","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-2562","authenticated-orcid":false,"given":"Robert","family":"Dodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7399-9907","authenticated-orcid":false,"given":"Shoshana","family":"Oberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3078-0454","authenticated-orcid":false,"given":"Jennifer","family":"Cunliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0196-4626","authenticated-orcid":false,"given":"Varun","family":"Ramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0578-1933","authenticated-orcid":false,"given":"Soumya","family":"Mohana Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4609-7085","authenticated-orcid":false,"given":"Ines C.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4133-898X","authenticated-orcid":false,"given":"Chongwoo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-085X","authenticated-orcid":false,"given":"Sanjay L.","family":"Dholakiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6845-3941","authenticated-orcid":false,"given":"Seema","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-1939","authenticated-orcid":false,"given":"Xiaohui Sophia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1561-0737","authenticated-orcid":false,"given":"Sasha","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-359X","authenticated-orcid":false,"given":"Zeinab","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1655-3542","authenticated-orcid":false,"given":"Feng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7344-2717","authenticated-orcid":false,"given":"David G.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9832-0078","authenticated-orcid":false,"given":"Omar S.","family":"Barnaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9021-9114","authenticated-orcid":false,"given":"Honglue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8289-3852","authenticated-orcid":false,"given":"Dominic E.","family":"Warrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-4276","authenticated-orcid":false,"given":"Shivangi","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1054-0628","authenticated-orcid":false,"given":"Krista","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4096-2705","authenticated-orcid":false,"given":"Stephanie","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7295-8512","authenticated-orcid":false,"given":"Alok","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"8","key":"1268_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, et al. Antibody\u2013drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1268_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4155\/bio.13.38","volume":"5","author":"B Gorovits","year":"2013","unstructured":"Gorovits B, et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis. 2013;5(9):997\u20131006.","journal-title":"Bioanalysis"},{"key":"1268_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-3-031-89319-3_6","volume-title":"Antibody Drug Conjugates: Design, Discovery, and Development","author":"Y-J Xue","year":"2026","unstructured":"Xue Y-J, et al. Bioanalytical Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugates. In: Gukasyan HJ, Kulkarni A, editors., et al., Antibody Drug Conjugates: Design, Discovery, and Development. Cham: Springer Nature Switzerland; 2026. p. 135\u201371."},{"issue":"2","key":"1268_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/17576180.2026.2631640","volume":"18","author":"W Xu","year":"2026","unstructured":"Xu W, Luo L, Matta M, Helmy R, Vazvaei-Smith F. Strategy for streamlining antibody-drug conjugate pharmacokinetic assays. Bioanalysis. 2026;18(2):179\u201388. https:\/\/doi.org\/10.1080\/17576180.2026.2631640.","journal-title":"Bioanalysis."},{"key":"1268_CR5","unstructured":"Clinical pharmacology considerations for antibody-drug conjugates, guidance for industry. 2024; Available from: https:\/\/www.fda.gov\/media\/155997\/download."},{"key":"1268_CR6","unstructured":"Technical guiding principles for clinical pharmacology studies of antibody\u2013drug conjugates (\u6297\u4f53\u5076\u8054\u836f\u7269\u4e34\u5e8a\u836f\u7406\u5b66\u7814\u7a76\u6280\u672f\u6307\u5bfc\u539f\u5219). 2025; Available from: https:\/\/www.cde.org.cn\/main\/att\/download\/26f36e5acbe1c2c7a124590e0feffdf3."},{"key":"1268_CR7","unstructured":"M10 bioanalytical method validation and study sample analysis, guidance for industry. 2022; Available from: https:\/\/www.fda.gov\/media\/162903\/download."},{"issue":"6","key":"1268_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.4155\/bio.14.36","volume":"6","author":"J Zheng","year":"2014","unstructured":"Zheng J, et al. Application and challenges in using LC\u2013MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery. Bioanalysis. 2014;6(6):859\u201379.","journal-title":"Bioanalysis"},{"issue":"1","key":"1268_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jim.2009.06.003","volume":"347","author":"AN Hoofnagle","year":"2009","unstructured":"Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods. 2009;347(1):3\u201311.","journal-title":"J Immunol Methods"},{"issue":"1","key":"1268_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-014-9685-5","volume":"17","author":"R Jenkins","year":"2015","unstructured":"Jenkins R, et al. Recommendations for validation of LC-MS\/MS bioanalytical methods for protein biotherapeutics. AAPS J. 2015;17(1):1\u201316.","journal-title":"AAPS J"},{"issue":"2","key":"1268_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1586\/14789450.2015.1024225","volume":"12","author":"JX Shen","year":"2015","unstructured":"Shen JX, Liu G, Zhao Y. Strategies for improving sensitivity and selectivity for the quantitation of biotherapeutics in biological matrix using LC-MS\/MS. Expert Rev Proteomics. 2015;12(2):125\u201331.","journal-title":"Expert Rev Proteomics"},{"key":"1268_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.chroma.2013.02.016","volume":"1284","author":"G Liu","year":"2013","unstructured":"Liu G, et al. Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: Practical considerations in assay development and validation. J Chromatogr A. 2013;1284:155\u201362.","journal-title":"J Chromatogr A"},{"issue":"9","key":"1268_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.4155\/bio.13.68","volume":"5","author":"S Kaur","year":"2013","unstructured":"Kaur S. Bioanalysis special focus issue on antibody-drug conjugates. Bioanalysis. 2013;5(9):981\u20133.","journal-title":"Bioanalysis"},{"issue":"6","key":"1268_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.4155\/bio.11.30","volume":"3","author":"JP Stephan","year":"2011","unstructured":"Stephan JP, Kozak KR, Wong WL. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis. 2011;3(6):677\u2013700.","journal-title":"Bioanalysis"},{"issue":"23","key":"1268_CR15","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.4155\/bio.14.279","volume":"6","author":"D Dufield","year":"2014","unstructured":"Dufield D, et al. <article-title update=\"added\">2014 white paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 \u2013 hybrid LBA\/LCMS, ELN & regulatory agencies\u2019 input). Bioanalysis. 2014;6(23):3237\u201349.","journal-title":"Bioanalysis"},{"issue":"4","key":"1268_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1208\/s12248-023-00835-0","volume":"25","author":"M-J Suh","year":"2023","unstructured":"Suh M-J, et al. Enhanced Pharmacokinetic Bioanalysis of Antibody\u2013drug Conjugates using Hybrid Immunoaffinity Capture and Microflow LC-MS\/MS. AAPS J. 2023;25(4):68.","journal-title":"AAPS J"},{"issue":"13","key":"1268_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4155\/bio-2016-0017","volume":"8","author":"J Wang","year":"2016","unstructured":"Wang J, et al. Antibody-drug conjugate bioanalysis using LB-LC-MS\/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays. Bioanalysis. 2016;8(13):1383\u2013401.","journal-title":"Bioanalysis"},{"issue":"1","key":"1268_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4155\/bio.15.230","volume":"8","author":"RJ Sanderson","year":"2016","unstructured":"Sanderson RJ, et al. Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates. Bioanalysis. 2016;8(1):55\u201363.","journal-title":"Bioanalysis"},{"key":"1268_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123844","volume":"1228","author":"F Yin","year":"2023","unstructured":"Yin F, et al. Development and validation of a hybrid immunoaffinity LC-MS\/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1228:123844.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"8","key":"1268_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/bmc.2759","volume":"26","author":"MT Furlong","year":"2012","unstructured":"Furlong MT, et al. A universal surrogate peptide to enable LC-MS\/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies. Biomed Chromatogr. 2012;26(8):1024\u201332.","journal-title":"Biomed Chromatogr"},{"key":"1268_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114319","volume":"205","author":"KAM de Jong","year":"2021","unstructured":"de Jong KAM, et al. Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS. J Pharm Biomed Anal. 2021;205:114319.","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"1268_CR22","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00216-015-9286-x","volume":"408","author":"C Lanshoeft","year":"2016","unstructured":"Lanshoeft C, et al. The use of generic surrogate peptides for the quantitative analysis of human immunoglobulin G1 in pre-clinical species with high-resolution mass spectrometry. Anal Bioanal Chem. 2016;408(6):1687\u201399.","journal-title":"Anal Bioanal Chem"},{"key":"1268_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jchromb.2016.12.044","volume":"1044\u20131045","author":"W Li","year":"2017","unstructured":"Li W, et al. LC-MS\/MS determination of a human mAb drug candidate in rat serum using an isotopically labeled universal mAb internal standard. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1044\u20131045:166\u201376.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1268_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123715","volume":"1223","author":"F Yin","year":"2023","unstructured":"Yin F, et al. Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LC-MS\/MS approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1223:123715.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"4","key":"1268_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1021\/bc049969t","volume":"15","author":"K Klussman","year":"2004","unstructured":"Klussman K, et al. Secondary mAb\u2013vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway. Bioconjug Chem. 2004;15(4):765\u201373.","journal-title":"Bioconjug Chem"},{"key":"1268_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jchromb.2015.08.007","volume":"1002","author":"A Liu","year":"2015","unstructured":"Liu A, et al. Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC-MS\/MS approach: Assay development, validation, and a case study. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1002:54\u201362.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2 Pt 1","key":"1268_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/1078-0432.843.11.2","volume":"11","author":"RJ Sanderson","year":"2005","unstructured":"Sanderson RJ, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2 Pt 1):843\u201352.","journal-title":"Clin Cancer Res"},{"key":"1268_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.687926","volume":"12","author":"D Su","year":"2021","unstructured":"Su D, Zhang D. Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency. Front Pharmacol. 2021;12: 687926. https:\/\/doi.org\/10.3389\/fphar.2021.687926.","journal-title":"Front Pharmacol."},{"issue":"3","key":"1268_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpha.2020.05.008","volume":"10","author":"X Zhu","year":"2020","unstructured":"Zhu X, et al. Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. J Pharm Anal. 2020;10(3):209\u201320.","journal-title":"J Pharm Anal"},{"key":"1268_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2022.116621","volume":"152","author":"T Liu","year":"2022","unstructured":"Liu T, et al. Analytical tools for antibody\u2013drug conjugates: From in vitro to in vivo. TrAC, Trends Anal Chem. 2022;152:116621.","journal-title":"TrAC, Trends Anal Chem"},{"issue":"10","key":"1268_CR31","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.1021\/acs.analchem.7b00408","volume":"89","author":"J He","year":"2017","unstructured":"He J, et al. High-Resolution Accurate-Mass Mass Spectrometry Enabling In-Depth Characterization of in Vivo Biotransformations for Intact Antibody-Drug Conjugates. Anal Chem. 2017;89(10):5476\u201383.","journal-title":"Anal Chem"},{"issue":"14","key":"1268_CR32","doi-asserted-by":"publisher","first-page":"7756","DOI":"10.1021\/acs.analchem.4c05885","volume":"97","author":"F Ma","year":"2025","unstructured":"Ma F, et al. Novel Native Reversed-Phase Liquid Chromatography (nRPLC)\/MS for Antibody-Drug Conjugates (ADCs) Characterization and Drug-Antibody Ratio (DAR) Assessment. Anal Chem. 2025;97(14):7756\u201364.","journal-title":"Anal Chem"},{"issue":"15","key":"1268_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9774","volume":"38","author":"Y Li","year":"2024","unstructured":"Li Y, et al. Intact quantitation of cysteine-conjugated antibody-drug conjugates using native mass spectrometry. Rapid Commun Mass Spectrom. 2024;38(15):e9774.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"1268_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27196299","author":"Q Qin","year":"2022","unstructured":"Qin Q, Gong L. Current analytical strategies for antibody-drug conjugates in biomatrices. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27196299.","journal-title":"Molecules"},{"issue":"12","key":"1268_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/17576180.2025.2529146","volume":"17","author":"L Guo","year":"2025","unstructured":"Guo L, et al. Impact of drug concentration and ADA assay drug tolerance on the assessment and correlation of titer and signal to noise. Bioanalysis. 2025;17(12):787\u201393.","journal-title":"Bioanalysis"},{"issue":"17","key":"1268_CR36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.4155\/bio-2018-0259","volume":"11","author":"M Carrasco-Triguero","year":"2019","unstructured":"Carrasco-Triguero M, et al. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials. Bioanalysis. 2019;11(17):1555\u201368.","journal-title":"Bioanalysis"},{"key":"1268_CR37","doi-asserted-by":"publisher","first-page":"1581153","DOI":"10.3389\/fimmu.2025.1581153","volume":"16","author":"J Grudzinska-Goebel","year":"2025","unstructured":"Grudzinska-Goebel J, et al. Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform. Front Immunol. 2025;16:1581153.","journal-title":"Front Immunol"},{"issue":"6","key":"1268_CR38","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/cpt.3573","volume":"117","author":"S Richards","year":"2025","unstructured":"Richards S, et al. IQ Survey Results on Current Industry Practices: Part 2-Quantitative Evaluations of Immunogenicity Assessment. Clin Pharmacol Ther. 2025;117(6):1605\u201313.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1268_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1208\/s12248-014-9684-6","volume":"17","author":"MB Hock","year":"2015","unstructured":"Hock MB, et al. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 2015;17(1):35\u201343.","journal-title":"AAPS J"},{"issue":"1","key":"1268_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1208\/s12248-023-00788-4","volume":"25","author":"D Fairman","year":"2023","unstructured":"Fairman D, Tang H. Best Practices in mAb and Soluble Target Assay Selection for Quantitative Modelling and Qualitative Interpretation. AAPS J. 2023;25(1):23.","journal-title":"AAPS J"},{"key":"1268_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2025.110941","volume":"138","author":"I Cheong","year":"2025","unstructured":"Cheong I, et al. Shortcoming of serum B-cell maturation antigen measurement by enzyme-linked immunosorbent assay in one laboratory\u2019s experience: Unsatisfactory assay reproducibility. Clin Biochem. 2025;138:110941.","journal-title":"Clin Biochem"},{"issue":"1","key":"1268_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/adt.2020.1024","volume":"19","author":"A Stauffer","year":"2021","unstructured":"Stauffer A, Ray C, Hall M. A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug. Assay Drug Dev Technol. 2021;19(1):17\u201326.","journal-title":"Assay Drug Dev Technol"},{"issue":"10","key":"1268_CR43","doi-asserted-by":"publisher","first-page":"741","DOI":"10.4155\/bio-2021-0066","volume":"13","author":"L Amaravadi","year":"2021","unstructured":"Amaravadi L. Critical reagents: evolution of WRIB recommendations on critical reagents. Bioanalysis. 2021;13(10):741\u20133.","journal-title":"Bioanalysis"},{"key":"1268_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26195847","author":"JTW Tong","year":"2021","unstructured":"Tong JTW, et al. An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26195847.","journal-title":"Molecules"},{"issue":"4\u20135","key":"1268_CR45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0731-7085(97)00256-2","volume":"17","author":"HM Dodds","year":"1998","unstructured":"Dodds HM, Robert J, Rivory LP. The detection of photodegradation products of irinotecan (CPT-11, Campto, Camptosar), in clinical studies, using high-performance liquid chromatography\/atmospheric pressure chemical ionisation\/mass spectrometry. J Pharm Biomed Anal. 1998;17(4\u20135):785\u201392.","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"1268_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics17111397","volume":"17","author":"S Luo","year":"2025","unstructured":"Luo S. Insights into Photo Degradation and Stabilization Strategies of Antibody-Drug Conjugates with Camptothecin Payloads. Pharmaceutics. 2025;17(11):1\u201319.","journal-title":"Pharmaceutics"},{"key":"1268_CR47","unstructured":"Bioanalytical method validation, guidance for industry. 2018; Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"issue":"5","key":"1268_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1208\/s12248-024-00974-y","volume":"26","author":"F Vazvaei-Smith","year":"2024","unstructured":"Vazvaei-Smith F, et al. ICH M10 Bioanalytical Method Validation Guideline-1 year Later. AAPS J. 2024;26(5):103.","journal-title":"AAPS J"},{"issue":"1","key":"1268_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4155\/bio.12.291","volume":"5","author":"X Xu","year":"2012","unstructured":"Xu X, et al. Fit-for-purpose bioanalytical cross-validation for LC\u2013MS\/MS assays in clinical studies. Bioanalysis. 2012;5(1):83\u201390.","journal-title":"Bioanalysis"},{"issue":"3","key":"1268_CR50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jpba.2005.06.020","volume":"40","author":"JX Shen","year":"2006","unstructured":"Shen JX, et al. Orthogonal extraction\/chromatography and UPLC, two powerful new techniques for bioanalytical quantitation of desloratadine and 3-hydroxydesloratadine at 25 pg\/mL. J Pharm Biomed Anal. 2006;40(3):689\u2013706.","journal-title":"J Pharm Biomed Anal"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01268-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:23Z","timestamp":1785521303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01268-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01268-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are employed by and receive compensation from their affiliations that are listed in this manuscript. The authors have no other relevant affiliations or financial involvements with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chongwoo Yu is an employee of the US FDA. The views expressed in this manuscript are his they do not reflect the official policy of the US FDA. No official endorsement by the US FDA is intended or should be inferred.\u00a0The views and conclusions presented in this paper are those of the authors and do not reflect those affiliated company\u2019s position on the subject.","order":2,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}